Report : North America Heart Transplant Market Forecast to 2030 - Regional Analysis - by Surgery Type (Orthotopic Heart Transplant and Heterotopic Heart Transplant), Type (Donor Live Heart and Artificial Hearts), and End User (Hospitals, Cardiac Centers, and Others)
At 11.4% CAGR, North America Heart Transplant Market is Projected to be Worth US$ 17,192.72 Million by 2030, says Business Market Insights
According to Business Market Insights research, the North America heart transplant market was valued at US$ 7,252.10 million in 2022 and is expected to reach US$ 17,192.72 million by 2030, registering a CAGR of 11.4% from 2022 to 2030. Increasing target disease incidence and growing geriatric population are among the critical factors attributed to the North America heart transplant market expansion.
The World Health Organization (WHO) states cardiovascular disease (CVD) is one of the leading causes of death worldwide. A few of the major contributors to the rising prevalence of CVDs are ethnicity, family history, and age. Other notable factors include increasing tobacco consumption, high cholesterol, hypertension; and diseases such as obesity, dyslipidemia, and diabetes. According to the WHO, deaths due to CVDs across the world will rise from ~17 million in 2016 to 23.6 million by 2030. Moreover, the global cost burden of CVDs would reach US$ 1,044 billion by 2030 from US$ 863 billion in 2010. As per the American Heart Association, ~40% of adults in the US are likely to have hypertension by 2030, recording an 8.4% increase from 2012. Emory Healthcare report states that the US recorded ~5 million cases of congestive failure in 2022, and ~550,000 new cases were diagnosed every year in the US. Also, the country reports ~287,000 deaths due to heart failure every year. In the US, nearly 3,499 people underwent heart transplant procedures in 2020. Data from an annual report on Cardiothoracic Organ Transplantation 2021/22, NHS Blood and Transplant, published September 2022, suggests that ~145 heart transplants were performed in adults in 2021-2022 in the UK. As per Temple Health, 70.9% of patients received heart transplant treatments within a year, and the shortest waitlist average was 55.2% in the US in 2021. Therefore, the rising incidence of CVDs and heart failure drives the growth of the heart transplant market.
On the contrary, high cost of surgeries hampers the growth of North America heart transplant market.
Based on surgery type, the North America heart transplant market is bifurcated into orthotopic heart transplantation and heterotopic heart transplantation. The orthotopic heart segment held 80.1% share of North America heart transplant market in 2022, amassing US$ 5,808.84 million. It is projected to garner US$ 13,978.85 million by 2030 to expand at 11.6% CAGR during 2022-2030.
In terms of type, the North America heart transplant market is bifurcated into donor live heart and artificial heart. The donor live heart segment held 70.9% share of North America heart transplant market in 2022, amassing US$ 5,140.40 million. It is projected to garner US$ 11,958.97 million by 2030 to expand at 11.1% CAGR during 2022-2030. Further, artificial heart segment is categorized into ventricular assisted device and total artificial heart.
Based on end user, the North America heart transplant market is segmented into hospitals, cardiac centers, and others. The hospitals segment held 58.5% share of North America heart transplant market in 2022, amassing US$ 4,242.25 million. It is projected to garner US$ 10,288.29 million by 2030 to expand at 11.7% CAGR during 2022-2030.
By country, the North America heart transplant market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 89.4% share of North America heart transplant market in 2022. It was assessed at US$ 6,486.28 million in 2022 and is likely to hit US$ 15,679.76 million by 2030, exhibiting a CAGR of 11.7% during 2022-2030.
Key players operating in the North America heart transplant market are Terumo Corp, Evaheart Inc, Abbott Laboratories, SynCardia Systems LLC, BiVACOR Inc, BioVentrix Inc, Berlin Heart GmbH, LivaNova Plc, Jarvik Heart Inc, and Calon Cardio-Technology Ltd, among others.
- In January 2022, BioVentrix Acquired MateraCor Inc and their lead product. MateraCor, Inc. is a company that uses injectable hydrogel based on alginate to stop the progression of heart failure and reverse it.
- In September 2021, SynCardia Systems performs inorganic growth strategies to reach more customers. The venture capital investment firm Hunniwell Lake Ventures, LLC, with its headquarters in California, acquired SynCardia. As a result, SynCardia now has the operational and financial means to guarantee its continued expansion and success both domestically and internationally. To assist more patients, the company has been able to continue creating cutting-edge medical devices and exploring new indications owing to this funding.
- In June 2020, Berlin Heart GmbH and SONOTEC partnered to develop a new type of clamp-on ultrasonic sensor enabling flow measurement for all EXCOR cannulae and pump variants in combination with the new mobile driving unit EXCOR Active. With its products EXCOR Adult and EXCOR Pediatric, Berlin Heart GmbH is the only company in the world to support patients of any age and body size - from infants to adults.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com